Drug name - Akynzeo

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6297375 HELSINN HLTHCARE 4-phenyl-pyridine derivatives
Mar, 2023

(5 months from now)

US10233154 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10961195 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US10676440 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

US9951016 HELSINN HLTHCARE Crystalline forms of an NK-1 antagonist
Sep, 2035

(12 years from now)

CN107001275A HELSINN HLTHCARE Form Of Nk-1 Antagonist
Nov, 2019

(2 years ago)

CN1142144C HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

CN1270959A HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

IN215447B HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

IN200000144I4 HELSINN HLTHCARE 4-Phenyl-Pyridine Derivatives
Feb, 2020

(2 years ago)

EP1394150A1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

EP1394150B1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

EP1035115B1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

EP1035115A1 HELSINN HLTHCARE 4-Phenylpyridine Derivatives And Their Use As Nk-1 Receptor Antagonists
Feb, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Dec, 2030

(8 years from now)

US9271975 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Sep, 2031

(8 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG;EQ 0.5MG BASE CAPSULE;ORAL Prescription
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(9 years from now)

US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(9 years from now)

US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

CN104053652A HELSINN HLTHCARE 4-Phenyl Pyridine For Treatment Of Nk-1 Receptor Related Disease
Nov, 2021

(10 months ago)

CN106518924A HELSINN HLTHCARE For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases
Nov, 2032

(10 years from now)

CN106986822A HELSINN HLTHCARE For Treatment Of Substituted 4-Phenyl Pyridinium Nk-1 Receptor Associated Diseases
Nov, 2032

(10 years from now)

CN106986822B HELSINN HLTHCARE Substituted 4-Phenylpyridine For The Treatment Of Nk-1 Receptor Related Diseases
Nov, 2032

(10 years from now)

CN106518924B HELSINN HLTHCARE 4 For Treating Substituted-Phenyl Pyridine Nk-1 Receptor Associated Diseases
Nov, 2032

(10 years from now)

IN201404907P4 HELSINN HLTHCARE Substituted-4- Phenyl Pyridines For The Treatment Of Nk 1 Receptor Related Diseases
Nov, 2032

(10 years from now)

IN324179B HELSINN HLTHCARE Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases
Nov, 2032

(10 years from now)

EP2785706A1 HELSINN HLTHCARE Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases.
Nov, 2032

(10 years from now)

EP2785706B1 HELSINN HLTHCARE Substituted 4-Phenyl-Pyridines For The Treatment Of Nk-1 Receptor Related Diseases.
Nov, 2032

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Dec, 2030

(8 years from now)

US8895586 HELSINN HLTHCARE Methods of treating emesis May, 2032

(9 years from now)

US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator May, 2032

(9 years from now)

US10624911 HELSINN HLTHCARE Physiologically balanced injectable formulations of fosnetupitant Jun, 2037

(14 years from now)

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL POWDER;INTRAVENOUS Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.